SPRINT Stock Overview
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Sprint Bioscience AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr1.25 |
| 52 Week High | kr3.28 |
| 52 Week Low | kr0.45 |
| Beta | 0.61 |
| 1 Month Change | 6.55% |
| 3 Month Change | 27.49% |
| 1 Year Change | 83.58% |
| 3 Year Change | -75.55% |
| 5 Year Change | -91.42% |
| Change since IPO | -92.18% |
Recent News & Updates
Shareholder Returns
| SPRINT | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -7.3% | -1.2% | -0.7% |
| 1Y | 83.6% | -5.1% | 8.7% |
Return vs Industry: SPRINT exceeded the Swedish Biotechs industry which returned -6.3% over the past year.
Return vs Market: SPRINT exceeded the Swedish Market which returned 8.1% over the past year.
Price Volatility
| SPRINT volatility | |
|---|---|
| SPRINT Average Weekly Movement | 13.8% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: SPRINT's share price has been volatile over the past 3 months.
Volatility Over Time: SPRINT's weekly volatility has decreased from 40% to 14% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 28 | Johan Emilsson | www.sprintbioscience.com |
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. It develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism, nash, and diabetes.
Sprint Bioscience AB (publ) Fundamentals Summary
| SPRINT fundamental statistics | |
|---|---|
| Market cap | kr87.41m |
| Earnings (TTM) | -kr438.00k |
| Revenue (TTM) | kr51.69m |
1.7x
P/S Ratio-199.6x
P/E RatioIs SPRINT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPRINT income statement (TTM) | |
|---|---|
| Revenue | kr51.69m |
| Cost of Revenue | kr8.70m |
| Gross Profit | kr42.99m |
| Other Expenses | kr43.43m |
| Earnings | -kr438.00k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0063 |
| Gross Margin | 83.17% |
| Net Profit Margin | -0.85% |
| Debt/Equity Ratio | 0% |
How did SPRINT perform over the long term?
See historical performance and comparison